Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) have shown experimentally what has been ...

Zepbound (tirzepatide) is only available on prescription for people with obesity, or those with overweight. Learn how to get Zepbound online, in-person, and through the drug’s manufacturer, Eli ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co ... that GLP-1 drugs currently require a regular injection, it's likely many patients will opt for a ...

Imagine this: You walk into your doctor and get your yearly flu vaccine and a yearly dose of your weight-loss injection ... prescribed for diabetes, and Zepbound, for obesity.

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as effective as bariatric surgery.

Eli Lilly and Co. reported that its FDA-approved weight-loss drug Zepbound (tirzepatide) outperformed Novo Nordisk A/S’s Wegovy (semaglutide) in the phase IIIb Surmount-5 trial.

Of note, however, at peak times, the oral DehydraTECH-tirzepatide-induced insulin levels were as much as approximately 100% higher than those from the Zepbound® injection. Richard Christopher, CEO, ...

NEW YORK, Jan. 22 (UPI) --As demand for weight-loss injections sold under brand names ... Related FDA approves weight-loss drug Zepbound to treat sleep apnea FDA says shortage of GLP-1 drug ...

This class of drugs, known as glucagon-like peptide-1 receptor agonists, or GLP-1s, also includes Wegovy and Zepbound. GLP-1s were developed to treat diabetes, but they have become popular weight ...

A new generation of obesity drugs – such as Novo Nordisk A/S’ Wegovy and Eli Lilly and Company’s Zepbound – is changing the perception of obesity as a multifaceted illness that requires ...